A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 in Patients With Advanced Solid Tumors With Liver Involvement.

Trial Profile

A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 in Patients With Advanced Solid Tumors With Liver Involvement.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2013

At a glance

  • Drugs ALN-VSP (Primary)
  • Indications Liver cancer; Liver metastases; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jan 2013 Results were published online in Cancer Discovery, according to an Alnylam Pharmaceuticals media release.
    • 15 May 2012 Final results will be presented at the Annual Meeting of the American Society of Clinical Oncology in June 2012.
    • 09 Feb 2012 Interim results from the first three patients enrolled in the extension protocol have been presented in an Alnylam Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top